SinglePass Study Reaches 500 Cases as Adoption Expands Across Biopsy Workflows
SinglePass Inc., a medical technology company dedicated to improving patient outcomes and procedural efficiency in interventional radiology, today announced that the B-S.A.F.E. (Biopsy Safety and Feasibility Evaluation) Study has reached 500 enrolled cases — the halfway point of its 1,000-case target.
